SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 or 15d-16 OFTHE SECURITIES EXCHANGE ACT OF 1934
DateApril 2, 2008_________________________________
BIOTECH HOLDINGS LTD.
(Exact name of Registrant as specified in its charter)
#160 - 3751 Shell Road, Richmond, British Columbia, Canada, V6X 2W2
(Address of principal executive offices)
Commission file number0-29108 _
(Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F)
Form 20-F Yes Form 40-F No
(Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.)
No
Biotech Holdings Ltd.
Filed in this Form 6-K
Documents index
News Release dated April 2, 2008
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
BIOTECH HOLDINGS LTD.
By: /s/ Robert Rieveley
Name: Robert Rieveley
Date: April 2, 2008
BIOTECH HOLDINGS ISSUES REPLACEMENT STOCK OPTIONS
Vancouver, B.C., April 2, 2008 - Biotech Holdings (the "Company", OTC BB: BIOHF; Frankfurt: 925970.F) announced today that the Company has granted 1,838,600 replacement options for 1,990,000 options which have expired or been cancelled. The granted options are divided among officers and directors (1,340,000), employees (360,000) and consultants (138,600).
All of the options have an exercise price of $.10 Cdn per share, vest October 31, 2008 and expire March 31, 2010.
The stock options described above comply with the Stock Option Plan approved by shareholders of the Company on September 30, 2005.
Biotech Holdings Ltd. is based in Richmond, British Columbia. Biotech Holdings shares trade on the Over the Counter Bulletin Board in the United States (OTC BB: BIOHF).
For inquiries, contact Austin Rand at Biotech Holdings Ltd., 1 888 216 1111 (toll-free), 8 a.m. to 5 p.m. Pacific time, or by e-mail atbiotech@direct.ca. For background information, please visit Biotech^s website at www.biotechltd.com.
This release has been approved by the Board of Directors of Biotech Holdings.
Any statements made in this release that are not based on historical fact are forward-looking statements. Any forward-looking statements made in this release represent management^s best judgement as to what may occur in the future. However, actual outcome and results are not guaranteed and are subject to certain risks, uncertainties and assumptions and may differ materially from what is expressed.
